Bipartisan Efforts to Cap Insulin Costs with the INSULIN Act

The INSULIN Act, introduced by Senators Jeanne Shaheen (D-N.H.), Raphael Warnock (D-Ga.), Susan Collins (R-Maine), and John Kennedy (R-La.), aims to cap the monthly cost of insulin at $35 for Americans with private insurance. This initiative comes in response to the rising costs of insulin, which can significantly burden families, particularly those with children suffering from Type 1 diabetes. The bill also proposes a pilot program to provide affordable insulin to uninsured Americans in ten states.

Associated Press

Despite previous legislative efforts, including a 2022 law that capped insulin costs for Medicare beneficiaries, many Americans still face high out-of-pocket expenses. Over half of U.S. states have enacted their own insulin co-pay caps, ranging from $25 to $100 per month. However, approximately 57% of Americans with private health insurance are on self-insured plans, which are not subject to state regulations, leaving them vulnerable to high costs. Major insulin manufacturers, such as Eli Lilly, Sanofi, and Novo Nordisk, have implemented various strategies to reduce prices, but access to these savings remains inconsistent.

Associated Press

Individuals like Bain Brandon, a two-year-old with Type 1 diabetes, and Breana Glover, a 23-year-old server, illustrate the financial strain of insulin costs. Glover, who moved to Texas for lower living expenses, manages her diabetes by limiting her carbohydrate intake to stretch her insulin supply. She views the proposed $35 cap as a crucial step toward greater accessibility, allowing her to allocate funds for other necessities like groceries and gas. Advocacy groups, including The Diabetes Link, emphasize the importance of this legislation for young adults, many of whom struggle to obtain quality health insurance.

Associated Press

While the INSULIN Act has garnered bipartisan support, its path to enactment is fraught with challenges. Previous attempts to pass similar legislation have stalled, including a 2022 House bill that aimed to cap insulin costs for those with private insurance but failed to progress in the Senate. Critics, including Dr. Leslie Eiland, an endocrinologist, highlight the burden placed on patients to navigate complex cost-saving programs. Additionally, pharmaceutical trade associations, such as PhRMA, point to barriers created by pharmacy benefit managers and insurers that hinder patient access to affordable medications.

Associated Press

Pharmaceutical companies have expressed their commitment to making insulin more affordable. Oliver Bogillot of Sanofi stated, “No one should struggle to afford their insulin,” while Flavia Brakling from Novo Nordisk emphasized the company's priority of expanding access to medicine. However, concerns remain about the effectiveness of these measures in reaching all patients.

Associated Press

The INSULIN Act represents a critical effort to address the escalating costs of insulin in the United States. Advocates remain hopeful, despite the potential for competing congressional priorities to overshadow the bill. As discussions continue, the focus remains on ensuring that all individuals with diabetes can access the lifesaving medication they need without financial hardship.

Associated Press